| Multiple Myeloma
Darzalex vs Xgeva
Side-by-side clinical, coverage, and cost comparison for multiple myeloma.Deep comparison between: Darzalex vs Xgeva with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXgeva has a higher rate of injection site reactions vs Darzalex based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xgeva but not Darzalex, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Darzalex
Xgeva
At A Glance
IV infusion
Weekly to every 4 weeks
Anti-CD38 monoclonal antibody
SC injection
Every 4 weeks
RANKL inhibitor
Indications
- Multiple Myeloma
- Multiple Myeloma
- Metastatic malignant neoplasm to bone
- Giant Cell Tumor of Bone
- Humoral hypercalcemia of malignancy (disorder)
Dosing
Multiple Myeloma 16 mg/kg IV; dosing schedule varies by combination regimen: weekly for initial doses (6-9 doses), then every 2-3 weeks, then every 4 weeks until disease progression; pre-medicate with corticosteroids, antipyretics, and antihistamines before each infusion.
Multiple Myeloma, Metastatic malignant neoplasm to bone 120 mg SC every 4 weeks in the upper arm, upper thigh, or abdomen.
Giant Cell Tumor of Bone, Humoral hypercalcemia of malignancy (disorder) 120 mg SC every 4 weeks with additional 120 mg doses on Days 8 and 15 of the first month of therapy, in the upper arm, upper thigh, or abdomen.
Contraindications
- History of severe hypersensitivity (e.g., anaphylactic reactions) to daratumumab or any of the formulation components
- Pre-existing hypocalcemia
- Known clinically significant hypersensitivity to Xgeva or denosumab products
Adverse Reactions
Most common (>=20%) Upper respiratory infection, neutropenia, infusion-related reactions, thrombocytopenia, diarrhea, constipation, anemia, peripheral sensory neuropathy, fatigue, peripheral edema, nausea, cough, pyrexia, dyspnea, asthenia
Serious Pneumonia, infusion-related reactions (Grade 3-4), neutropenia, thrombocytopenia, febrile neutropenia, sepsis
Postmarketing Anaphylactic reaction, infusion-related reactions (including deaths), pancreatitis, cytomegalovirus, listeriosis
Most common (>=25%) Fatigue/asthenia, hypophosphatemia, nausea
Serious Dyspnea, osteonecrosis of the jaw, hypocalcemia, atypical subtrochanteric and diaphyseal femoral fracture, multiple vertebral fractures following treatment discontinuation
Postmarketing Severe symptomatic hypocalcemia (including fatal cases), severe symptomatic hypercalcemia following treatment discontinuation, hypersensitivity including anaphylactic reactions, severe musculoskeletal pain, lichenoid drug eruptions, alopecia
Pharmacology
Anti-CD38 monoclonal antibody; daratumumab is an IgG1k human mAb that binds CD38 on tumor cells and induces apoptosis via Fc-mediated cross-linking and immune-mediated lysis through complement dependent cytotoxicity (CDC), antibody dependent cell mediated cytotoxicity (ADCC), and antibody dependent cellular phagocytosis (ADCP).
Xgeva is a RANKL inhibitor; it binds to RANKL, a protein essential for osteoclast formation, function, and survival, thereby preventing osteoclast-mediated bone resorption and modulating calcium release from bone in solid tumor bone metastases, multiple myeloma, giant cell tumor of bone, and hypercalcemia of malignancy.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Darzalex
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
Xgeva
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Darzalex
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Xgeva
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Darzalex
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Xgeva
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Acute Lymphoblastic Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Xgeva.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DarzalexView full Darzalex profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.